Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. Glecaprevir, one of the two DAAs in Mavyret, was Discovered ...

Results of a phase IIIb study found the direct-acting antiviral combination of glecaprevir/pibrentasvir to be highly effective and well tolerated in adults with acute ...

Countries are making measurable progress in combatting viral hepatitis, but the disease remains a major global health ...

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the ...

Whether hepatitis resolves depends on the type and whether a person receives treatment. Hepatitis A usually resolves without medications, and while sometimes hepatitis B and C may last only a few ...

Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...

Hepatitis C infection. Computer illustration showing liver and close-up view of hepatitis C viruses. Studies show that mortality, morbidity, and hepatic decompensation risks increase with coinfection ...

Fluctuations in circulating hepatitis C virus RNA could be "clinically meaningful" in a substantial number of patients with chronic infection, and could influence the best time to prescribe antiviral ...

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the disease remains a major global health challenge, according to a new World Health ...

Countries are making measurable progress in combatting viral hepatitis, but the disease remains a major global health challenge, the World Health Organization (WHO) said in a new report published on ...